Multiple SclerosisLMT-BENCT07868887
Validity and Reliability of the Language Memory Test (LMT) in Belgium
An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel.
Trial summary
This study aims to evaluate the practical and research utility of a new test assessing language and memory in people with MS. To this end, we are administering the test to a group of 100 individuals with MS who are receiving treatment at the National MS Center Melsbroek. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 19 Oct 2026to Feb 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult people diagnosed with multiple sclerosis (PwMS), treated in a multidisciplinary rehabilitation program in the National Multiple Sclerosis Center (NMSC) Belgium. Healthy (no MS diagnosis) adults matched for age, gender and education
Who may be able to join
- Native Dutch speaking
- Sufficient visual function (capacity to perceive test stimuli)
- Minimal single hand function to execute test responses
- Cognitive capacity to apprehend test instructions
Who cannot join
- Insufficient visual function (capacity to perceive test stimuli)
- Inability to perform single-hand motor movements required to complete the test (e.g., tapping, selecting responses)
- Insufficient cognitive capacity to understand or follow test instructions
- For PwMS:
- MS relapse more recently than three months
About this study
Official title: Assessing the Validity and Reliability of the Language Memory Test for Use in a Belgian Population of People With Multiple Sclerosis
This study aims to evaluate the practical and research utility of a new test assessing language and memory in people with MS. To this end, we are administering the test to a group of 100 individuals with MS who are receiving treatment at the National MS Center Melsbroek.
These data will allow us to determine whether scores on the new test correlate with those of established cognitive tests. Subsequently, we will administer the new test to 100 individuals without an MS diagnosis who are matched for age, gender, and education level. This will enable us to assess whether there are significant differences in scores between individuals with MS and those without the diagnosis.
One year later, we will re-administer the tests to the participants with MS to determine the extent to which changes in scores on the new test correspond to changes in scores on established tests.
- Conditions
- Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adults diagnosed with multiple sclerosis | Treated in a the National MS Center rehabilitation center | |
| Adults without MS diagnosis | matched for age, gender and educational level |
What is being measured
The primary outcome is the main question the study is designed to answer.
Language and Memory Test (LMT)
The LMT is a brief multidomain test assessing finger tapping speed, rapid lexical access, and visuospatial memory, designed for MS populations.
Measured: Baseline, after one week and and after one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2026
- Study start19 Oct 2026 (estimated)
- Primary completionFeb 2028 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Sponsor type
- University, hospital or other
- Collaborators
- National Multiple Sclerosis Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07868887
- Sponsor's protocol ID
- 26019_LMT-BE
- Acronym
- LMT-BE
- Status last verified
- Sep 2026
- First submitted
- 5 Oct 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Leavitt VM, Simani L, Koch M, Morrow SA, Heuer L, Roozbeh M, Roozbeh M, Traynor S. The language and memory test: A brief multidomain digital cognitive measure for multiple sclerosis. Mult Scler. 2025 Oct;31(11):1348-1357. doi: 10.1177/13524585251366096. Epub 2025 Sep 25.
PubMed 40995746
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Validity and Reliability of the Language Memory Test for Use in a Belgian Population of People With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07868887
- Acronym / sponsor ID
- LMT-BE / 26019_LMT-BE
- Conditions
- Multiple Sclerosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Universitair Ziekenhuis BrusselUniversity, hospital or other
- Collaborators
- National Multiple Sclerosis Center
- Study start
- 19 Oct 2026 (estimated)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 9 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the practical and research utility of a new test assessing language and memory in people with MS. To this end, we are administering the test to a group of 100 individuals with MS who are receiving treatment at the National MS Center Melsbroek.
These data will allow us to determine whether scores on the new test correlate with those of established cognitive tests. Subsequently, we will administer the new test to 100 individuals without an MS diagnosis who are matched for age, gender, and education level. This will enable us to assess whether there are significant differences in scores between individuals with MS and those without the diagnosis.
One year later, we will re-administer the tests to the participants with MS to determine the extent to which changes in scores on the new test correspond to changes in scores on established tests.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adults diagnosed with multiple sclerosis | – | –Treated in a the National MS Center rehabilitation center |
| Adults without MS diagnosis | – | –matched for age, gender and educational level |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult people diagnosed with multiple sclerosis (PwMS), treated in a multidisciplinary rehabilitation program in the National Multiple Sclerosis Center (NMSC) Belgium. Healthy (no MS diagnosis) adults matched for age, gender and education
Key inclusion criteria (4 listed)
- Native Dutch speaking
- Sufficient visual function (capacity to perceive test stimuli)
- Minimal single hand function to execute test responses
- Cognitive capacity to apprehend test instructions
Key exclusion criteria (5 listed)
- Insufficient visual function (capacity to perceive test stimuli)
- Inability to perform single-hand motor movements required to complete the test (e.g., tapping, selecting responses)
- Insufficient cognitive capacity to understand or follow test instructions
- MS relapse more recently than three months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Language and Memory Test (LMT)
Time frame: Baseline, after one week and and after one year
The LMT is a brief multidomain test assessing finger tapping speed, rapid lexical access, and visuospatial memory, designed for MS populations.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Background: PubMed 40995746Leavitt VM, Simani L, Koch M, Morrow SA, Heuer L, Roozbeh M, Roozbeh M, Traynor S. The language and memory test: A brief multidomain digital cognitive measure for multiple sclerosis. Mult Scler. 2025 Oct;31(11):1348-1357. doi: 10.1177/13524585251366096. Epub 2025 Sep 25.
Related trials for Multiple Sclerosis
Active, not recruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
RecruitingObservational study
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Language and Memory Test (LMT) (time frame: Baseline, after one week and and after one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07868887, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.